Large Chinese CROs To Benefit From Continued Outsourcing Trend, CRO Surveys Say
This article was originally published in PharmAsia News
As Big Pharma continues its restructuring initiatives to outsource services to lower-cost emerging markets, Chinese and U.S. contract research organizations with the largest footprints and broadest capabilities will benefit from the ongoing trend, according to two recently released surveys on the CRO industry
You may also be interested in...
China’s second-largest CRO opens new Shanghai facility to support its largest client.
Acquisition of BeijingWits will boost ICON’s clinical trial capabilities in China and the Asia Pacific region.
After Launching Corporate Venture Fund, WuXi Shifts Attention To China’s Domestic Market: China Earnings Roundup (Part 2)
China’s leading CRO grows revenues 24% in Q3, and establishes corporate venture fund to invest in homegrown innovation